Related Experiment Video

Updated: Aug 20, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Apolipoprotein L-I is positively associated with hyperglycemia and plasma triglycerides in CAD patients with low HDL

Timothy S E Albert1, Philippe N Duchateau, Samir S Deeb

  • 1Department of Medicine, University of Washington, Seattle, WA, USA.

Journal of Lipid Research
|December 18, 2004
PubMed

Insights

Plasma triglycerides and hyperglycemia significantly predict apolipoprotein L-I (apoL-I) levels in coronary artery disease patients. Antioxidant vitamins increased apoL-I, while statin therapy did not affect it.

Area of Science:

  • Biochemistry
  • Cardiovascular Disease Research
  • Lipid Metabolism

Background:

  • Apolipoprotein L-I (apoL-I) is associated with high-density lipoprotein (HDL) particles and plasma triglycerides (TGs).
  • Understanding apoL-I determinants is crucial in dyslipidemic populations, particularly those with coronary artery disease (CAD).

Purpose of the Study:

  • To identify biological determinants of plasma apoL-I levels in patients with coronary artery disease and low HDL.
  • To investigate the impact of hyperglycemia and lipid parameters on apoL-I levels.

Main Methods:

  • Plasma apoL-I levels were measured in 136 CAD subjects enrolled in a prevention trial.
  • Multivariate analysis was used to identify predictors of apoL-I, including VLDL-TG and hyperglycemia (HG).
  • The effect of simvastatin-niacin therapy and antioxidant vitamins on apoL-I levels was assessed.

Main Results:

  • Plasma apoL-I levels were positively correlated with VLDL-TG and hyperglycemia (HG).
  • Hyperglycemic patients exhibited over 50% higher mean apoL-I levels compared to normoglycemic subjects.
  • Antioxidant vitamins significantly increased apoL-I levels, whereas simvastatin-niacin therapy did not.

Conclusions:

  • Triglycerides (TG) and hyperglycemia (HG) are the primary predictors of apoL-I in dyslipidemic CAD patients.
  • These findings contribute to characterizing the novel HDL-associated apoL-I and its relationship with metabolic factors.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...